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Intraoperative radionuclide detection using "'In-DTPA-D-Phel-octreotide was
evaluated in five patients with midgut carcinoids and in three patients with
recurrent medullary thyroid carcinoma. Three different time intervals (24, 48
and 120 hr) from injection of the radiopharmaceutical to surgery were used. At
surgery, suspect tumors were measured by probe in situ and ex vivo after exci-
sion. All tissue specimens and blood samples withdrawn during surgery were
measured for "'In activity, and tissue/blood activity concentration ratios were
calculated. In situ measurements were valuable especially in neck surgery,
where the probe was helpful not only in localization of tumors but also in the
control of tumor clearance. Ex vivo measurements were helpful in diagnosing
tumor tissue. All five patients with midgut carcinoids were somatostatin recep-
tor-positive, while only three out of seven patients with medullary thyroid car-
cinoma were receptor-positive. The tissue/blood activity concentration ratios
and probe measurement ratios were in general higher in patients with midgut
carcinoid than in patients with medullary thyroid carcinoma. Of particular
interest were the high tissue/blood concentration ratios in all receptor-positive
patients at all time intervals studied. This fact suggests a potential role for radi-
olabelled octreotide in radiotherapy ofthese tumor types.
INTRODUCTION
Somatostatin is a dimer of a 14 amino acid peptide hormone with almost universal
distribution in the body and general suppressive effects on gastrointestinal function.
Somatostatin receptors are abundant on neuroendocrine cells but may also occur on non-
related cells, e.g., lymphocytes [1]. In neoplasia, very high numbers of somatostatin
receptors were demonstrated on neuroendocrine tumors using autoradiography of tumor
biopsies or binding to tumor cell membranes [2, 3]. Tumor binding of octreotide, a long-
acting analogue of somatostatin, has formed the basis for a new clinical imaging tech-
nique, octreotide scintigraphy. In the early development of this technique, radioiodine
(123I and 1251) was attached to a tyrosine residue, replacing phenylalanine in the receptor-
binding site ofthe octreotide molecule [4, 5]. In the currently used construction, the intact
octreotide molecule is labelled with "'In using diethylene-triamine-pentaacetic acid
(DTPA)b as the chelating agent. This labelling method influences the receptor-binding
site minimally and has increased the imaging sensitivity [6, 7].
Today five types of human somatostatin receptors have been cloned [8-11]. Type I
mainly occurs in the stomach andjejunum; type II in the brain and kidneys; type III in the
brain and pancreatic islets and type IV in the brain. All receptor types belong to the
aTo whom all correspondence should be addressed: Bo Wangberg, M.D., Ph.D., Dept. of Surgery,
Sahlgrenska University Hospital, 41345 Goteborg, Sweden. Tel: (46) 31-601000; Fax: (46) 31-
413892.
bAbbreviations used: DTPA, diethylene-triamine-pentaacetic acid; CT/US, computed tomography
and ultrasound; MC, midgut carcinoid; MTC, medullary thyroid carcinoma; Ti, tissue; B, blood; T,
tumor tissue; N, normal tissue.
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superfamily ofreceptors with seven transmembrane domains and are coupled with G-pro-
teins. Octreotide inhibits somatostatin binding to the receptor type II. At this stage, it can-
not be excluded that octreotide scintigraphy may also visualize other receptors than type
II.
We have previously shown that "'In-DTPA'D-Phel-octreotide scintigraphy has a
specificity and sensitivity (86 percent) superior to that of CT/US in the detection of
midgut carcinoid tumors (MC). Previously unrecognized tumors were visualized in 19
out of 27 patients [12]. Besides liver metastases, the most common uptake sites were
abdominal paraortic, supraclavicular and mediastinal lymph node metastases. The scinti-
graphic detection ofnovel tumor sites changed our clinical handling ofnine MC patients.
These patients were subjected to repeat surgery leading to complete remission in five
patients when evaluated biochemically and by postoperative scintigraphy. One major
advantage of "'In-DTPA-D-Phel-octreotide scintigraphy is that one single dose of the
radiopharmaceutical can be used both for diagnostic purposes preoperatively and for
evaluation ofthe result ofsurgical treatment postoperatively [12, 13].
In the present study we report on the clinical use of a scintillation detector for intra-
operative localization of tumors in patients with MC and medullary thyroid carcinoma
(MTC).
MATERIALS AND METHODS
Protocol
Tumor localization was assessed in 12 patients by scintigraphy and intraoperative
scintillation detection after i.v. injection of "'In-DTPA-D-Phel-octreotide. Scintigraphy
was performed prior to surgery in all patients and also one to two days after surgery with-
out iterated injection of the radiopharmaceutical. As the optimal interval between injec-
tion and surgery has not yet been established, three different time intervals (24, 48 and
120 hr) were used in this study.
Patients
Five patients had MC with lymph node and hepatic metastases. Two ofthese patients
(Numbers 1 and 2) had previously undergone intestinal resection and clearance ofregion-
al lymph node metastases and had received embolization therapy of the hepatic metas-
tases. The other three patients had recently diagnosed metastatic disease and underwent
primary surgery. Seven patients had previously undergone total thyroidectomy with
regional lymph node clearance due to MTC. They had subsequently undergone one to
four neck dissections due to recurrent tumors.
Scintigraphy
All five patients with MC had octreotide treatment, which was discontinued three
days prior to injection ofthe radiopharmaceutical. Each one ofthe 12 patients received 20
pg of 'I1n DTPA-D-Phel-octreotide by i.v. injection. The administered activity was 190-
350 MBq. A gamma camera (General Electric, 400 AC/T) equipped with a medium ener-
gy parallel hole collimator connected to a GE STARCAM computer system was used.
Data acquisition was performed in a dual window setting of 173 and 247 keV and evalu-
ated on a GE STAR 3000 system. Static anterior and posterior images from the base of
the skull to the pelvis were taken in all patients at 24 hr after injection. Static images were
acquired in a 128 x 128 matrix for 10 min, or until 500 kcounts were collected. Single
photon emission computed tomography (SPECT) was also performed using a 128 x 128
matrix and 360 degree rotation in 64 steps with 30 sec/step. Pre-filtration was performed
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using a Hanning filter with a cut-off frequency of 0.7 cm-1, and transaxial slices were
reconstructed with a ramp filter.
Intraoperative measurements
The scintillation detector system (TecProbe 2000, Stratec Elektronik, Germany) was
equipped with a handheld 17 x 2 cm silver-anodized aluminum tube. The tip ofthe probe
contained a CsI crystal collimated with a lead shield (aperture diameter of 8 mm over a
length of 10 mm). The probe was connected to a portable ratemeter. The energy window
was 140-200 keV, and measurement time could be chosen between 0.5 and 600 sec. A
sterile dressing was drawn over the probe, which was held close to the tissue examined.
To avoid contribution of activity from other tissues (e.g., liver, spleen and kidney) the
probe was directed away from these tissues ifpossible. With the scintillation detector, the
mean count rate in situ over the suspect lesion was recorded, as was the count rate over
adjacent normal tissue. The ratio, Rin situ' between the two measurements was calculated.
The count rates of excised tumor and normal tissue were also measured ex vivo with the
probe, and the corresponding ratio, Rexvivo, was calculated (cf. 12).
Measurements on tissue samples
Before histopathological examination, the surgical specimens were weighed and the
"'1In activity was measured in a calibrated gamma counter equipped with Na(TI) well
crystal (diameter 7.6 cm, length 7.6 cm, Harshaw, Holland). The hole in the crystal had a
diameter of 3 cm and a depth of 6 cm. A single-channel pulse-height analyzer (Elscint,
Israel) was used. Corrections were made for background activity and radioactivity decay.
Blood samples withdrawn during surgery were weighed and measured for "'1In activity.
Tissue (Ti) to blood (B) activity concentration ratios, Ti/B, were calculated.
Statistical analyses
The standard deviation of the difference between the mean number of counts from
suspect tumor tissue (T) and normal tissue (N) was estimated:
a= XT+ N = XT'*tT*nT+ N'*tNnN
where T' and N' are mean count rates from suspect tumor tissue and normal tissue, tT and
tN are measurement times, and nT and nN number of measurements for suspect tumor tis-
sue and normal tissue, respectively. Ifthe difference between the mean numbers ofcounts
from suspect tumor tissue and normal tissue exceeded two standard deviations of the dif-
ference, there was a 95 percent chance that this difference was not due to random error
alone. This difference was regarded as statistically significant (p < .05).
RESULTS
All five patients with MC tumors had a receptor-positive preoperative scintigraphy.
A positive scintigraphy in the region of planned surgery was found in only three out of
seven patients with MTC tumors (Table 1). Four of the MC patients underwent laparoto-
my and tumor reduction, while one patient had cervical and mediastinal metastases and
underwent neck and mediastinal exploration. All MTC patients underwent neck dissec-
tion due to recurrent disease. The Table shows the results of probe measurements from
patients with positive scintigraphic findings. No new tumor sites besides those identified
by scintigraphy were found. The Ti/B ratios relate to normal tissue and surgical speci-
mens with positive histopathological findings.
Our first patient (Number 1) with MC tumor had neck lesions. During dissection, the
probe was helpful not only in the localization oflesions but also in the control ofadequate218 Ahlman etal.: Somatostatin receptors on neuroendocrine twmors
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Figure 1. Results from intraoperative radionuclide detection of tumor/normal tissue before
(Ri situ) and after excision (Ri Vivo) and determination of tissue/blood activity concentration
ratios (Ti/B) in a patient with medullary thyroid carcinoma undergoing neck dissection.
Asterisks indicate statistically significant elevated ratios (p < .05).
clearance of tumor tissue. This was also the case in two (Numbers 6 and 8) of the three
patients with somatostatin receptor positive MTC tumors (Figure 1). In abdominal surgery
of patients with MC tumors, the probe measurements in situ were difficult to evaluate due
to relatively high background activity in parenchymatous organs (liver, kidney and
spleen). The discrimination between tumor and normal tissue in situ was better in the
pelvic region. In all cases, Rexvivo measurements ofbiopsies were reliable in distinguishing
between tumor and normal tissue.
There were no evident changes of Rinsitu, Rex vivo and Ti/B concentration ratios over
time, neither for normal nor for tumor tissue. As seen in the Table, the Rin situ values for
lymph node metastases of MC tumors were clearly higher than the corresponding values
of MTC tumors. Rex vivo values for both kinds of tumors were higher than the Rinsitu val-
ues. A marked difference was noted for the Ti/B ratio: MC tumors had a value 12 times
higher than for normal tissue, while for MTC tumors, five times higher values were seen.
DISCUSSION
The clinical value of octreotide scintigraphy in our previous diagnostic series was
confirmed by the detection of recurrent disease in MC patients assumed to be in complete
remission at conventional work-up [12]. The obvious advantage of 1In-DTPA-D-Phel-
octreotide scintigraphy vs. CT/US is the high sensitivity in combination with the whole
body screening for tumors [7, 12, 13]. The sensitivity for lymph node metastases is of
particular value in MTC patients, since small neck lesions often are difficult to detect by
radiological examinations.
The success rate of octreotide scintigraphy relies on the presence of somatostatin
receptors in the human tissue. In the vast Rotterdam experience of octreotide scintigra-
phy, 86 percent of patients with histologically proven MC had known tumor sites visual-
ized. The corresponding figure for MTC patients was 65 percent [14]. In the present
series, all five patients with MC tumor had positive scintigraphic findings, while three out
of seven patients with MTC had positive findings. Several factors interfering with the
visualization of somatostatin receptors have been discussed: endogenous tumor produc-
tion of somatostatin (MTC), concomitant therapy with octreotide leading to competition
or down-regulation, of somatostatin receptors (MC) [14]. In two previous patients with
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foregut carcinoid tumors, we have noted the occurrence of both scintigraphically positive
and negative metastases, probably reflecting variable differentiation grades [13]. Presence
of different subtypes of receptors for specific tumors must also be taken into considera-
tion (MTC) [14, 15].
Intraoperative probe measurements did not give information about other tumor sites
than those revealed by preoperative scintigraphy. However, the local extension of tumor
growth was clearly outlined by the probe, and successful tumor clearance was thus facili-
tated. The sensitivity of intraoperative scintillation detection depends on biological fac-
tors (e.g., the relations between the concentration ofradionuclide in tumor and non-tumor
tissues and how these relations are influenced by time) and also on the choice ofradionu-
clide and the performance ofthe detector system.
Since the concentration in plasma activity decreased six-fold between four and 24 hr
after injection, the optimal time for tumor imaging would be at 24 hr or later [16]. Our
Ti/B ratios and Rinsitu and Rex vivo ratios seemed to be little influenced by time when stud-
ied at 24, 48 and 120 hr. This indicates similar decline in radioactivity of tumor and non-
tumor tissue, or blood, after the initial 24 hours. Considering the high Ti/B ratios for
tumors, in comparison with the moderate ratios from the probe measurements, technical
improvements should be done. For our detector system, we suggest the possibility of
choosing a more suitable energy window and a collimator more appropriate for the detec-
tion of small tumors. Another way would be to use octreotide labelled with another
radionuclide emitting photons with lower energies. Such improvements would reduce the
contribution from primary and scattered photons from adjacent tissues [12].
The ex vivo measurements of excised tissue discriminated most reliably between
tumor-positive and tumor-negative lymph nodes. This suggests that this technique can be
used as a rapid complement to frozen tissue biopsies.
The high Ti/B activity concentration ratios observed indicate a potential role ofradio-
labelled octreotide for tumor therapy. This possibility can first be explored after detailed
pharmacokinetic and dosimetric studies ofoctreotide labelled with a suitable radionuclide.
B
Figure 2. Scintigraphic imaging of neck metastases of midgut carcinoid tumor. (A) 48 hr after
injection of 1311-Tyr3-octreotide supraclavicular and mediastinal metastases were indicated. The
patient underwent neck dissection but no mediastinal exploration. (B) Control scintigraphy was
performed 6 months later using tttIn-DTPA-Phel-octreotide. The image 48 hr after injection of the
radiopharmaceutical clearly demonstrates clearance of neck metastases but persistent mediastinal
metastases.
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In 1991, we performed our first diagnostic scintigraphies in seven patients with MC
tumors using 131I-labelled Tyr3-octreotide.The image quality was low, as expected, but in
three patients, the uptake in tumor tissue corresponded well with the uptake of IllIn-
DTPA-D-Phel-octreotide studied six to 12 months later. One patient underwent surgery for
neck metastases, which were first visualized by 131I-Tyr3-octreotide (Figure 2). For radio-
therapeutical purposes, however, fr-emitting radionuclides other than 1311 ought to be con-
sidered as first choices.
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